Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

AXS vs PRE vs EXAS vs RNR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AXS
AXIS Capital Holdings Limited

Insurance - Property & Casualty

Financial ServicesNYSE • BM
Market Cap$7.32B
5Y Perf.+95.2%
PRE
Prenetics Global Limited

Medical - Diagnostics & Research

HealthcareNASDAQ • HK
Market Cap$242M
5Y Perf.-85.9%
EXAS
Exact Sciences Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$20.02B
5Y Perf.-4.1%
RNR
RenaissanceRe Holdings Ltd.

Insurance - Reinsurance

Financial ServicesNYSE • BM
Market Cap$12.98B
5Y Perf.+97.0%

AXS vs PRE vs EXAS vs RNR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AXS logoAXS
PRE logoPRE
EXAS logoEXAS
RNR logoRNR
IndustryInsurance - Property & CasualtyMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchInsurance - Reinsurance
Market Cap$7.32B$242M$20.02B$12.98B
Revenue (TTM)$6.61B$69M$3.25B$11.49B
Net Income (TTM)$1.07B$-47M$-208M$3.09B
Gross Margin40.5%47.2%69.7%44.6%
Operating Margin19.6%-62.9%-6.4%35.5%
Forward P/E7.5x582.8x7.7x
Total Debt$1.49B$2M$2.52B$2.33B
Cash & Equiv.$820M$32M$956M$1.73B

AXS vs PRE vs EXAS vs RNRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AXS
PRE
EXAS
RNR
StockJul 21May 26Return
AXIS Capital Holdin… (AXS)100195.2+95.2%
Prenetics Global Li… (PRE)10014.1-85.9%
Exact Sciences Corp… (EXAS)10095.9-4.1%
RenaissanceRe Holdi… (RNR)100197.0+97.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: AXS vs PRE vs EXAS vs RNR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AXS leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Prenetics Global Limited is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. RNR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
AXS
AXIS Capital Holdings Limited
The Insurance Pick

AXS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 1 yrs, beta 0.12, yield 1.8%
  • Lower volatility, beta 0.12, Low D/E 23.5%, current ratio 1.58x
  • Beta 0.12, yield 1.8%, current ratio 1.58x
  • Lower P/E (7.5x vs 582.8x)
Best for: income & stability and sleep-well-at-night
PRE
Prenetics Global Limited
The Growth Play

PRE is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 201.7%, EPS growth -14.0%, 3Y rev CAGR 91.5%
  • 201.7% revenue growth vs AXS's 9.1%
  • +205.2% vs AXS's +1.0%
Best for: growth exposure
EXAS
Exact Sciences Corporation
The Lower-Volatility Pick

EXAS lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
RNR
RenaissanceRe Holdings Ltd.
The Insurance Pick

RNR is the clearest fit if your priority is long-term compounding.

  • 176.9% 10Y total return vs EXAS's 16.7%
  • 26.9% margin vs PRE's -67.4%
  • 5.7% ROA vs PRE's -23.7%, ROIC 16.0% vs -20.8%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthPRE logoPRE201.7% revenue growth vs AXS's 9.1%
ValueAXS logoAXSLower P/E (7.5x vs 582.8x)
Quality / MarginsRNR logoRNR26.9% margin vs PRE's -67.4%
Stability / SafetyAXS logoAXSBeta 0.12 vs PRE's 0.27
DividendsAXS logoAXS1.8% yield, 1-year raise streak, vs RNR's 0.6%, (2 stocks pay no dividend)
Momentum (1Y)PRE logoPRE+205.2% vs AXS's +1.0%
Efficiency (ROA)RNR logoRNR5.7% ROA vs PRE's -23.7%, ROIC 16.0% vs -20.8%

AXS vs PRE vs EXAS vs RNR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AXSAXIS Capital Holdings Limited
FY 2025
Insurance
75.1%$4.3B
Reinsurance
24.9%$1.4B
PREPrenetics Global Limited

Segment breakdown not available.

EXASExact Sciences Corporation
FY 2025
Screening
77.9%$2.5B
Precision Oncology
22.1%$717M
RNRRenaissanceRe Holdings Ltd.
FY 2025
Casualty and Specialty Segment
59.9%$5.9B
Property Segment
40.1%$4.0B

AXS vs PRE vs EXAS vs RNR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLRNRLAGGINGEXAS

Income & Cash Flow (Last 12 Months)

RNR leads this category, winning 4 of 6 comparable metrics.

RNR is the larger business by revenue, generating $11.5B annually — 166.5x PRE's $69M. RNR is the more profitable business, keeping 26.9% of every revenue dollar as net income compared to PRE's -67.4%. On growth, PRE holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
RevenueTrailing 12 months$6.6B$69M$3.2B$11.5B
EBITDAEarnings before interest/tax$1.4B-$54M-$41M$4.1B
Net IncomeAfter-tax profit$1.1B-$47M-$208M$3.1B
Free Cash FlowCash after capex$169M$0$357M$4.2B
Gross MarginGross profit ÷ Revenue+40.5%+47.2%+69.7%+44.6%
Operating MarginEBIT ÷ Revenue+19.6%-62.9%-6.4%+35.5%
Net MarginNet income ÷ Revenue+16.2%-67.4%-6.4%+26.9%
FCF MarginFCF ÷ Revenue+2.6%-23.8%+11.0%+36.7%
Rev. Growth (YoY)Latest quarter vs prior year+12.0%+2.0%+23.1%-36.4%
EPS Growth (YoY)Latest quarter vs prior year+45.6%+36.9%+90.4%+100.9%
RNR leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

RNR leads this category, winning 4 of 6 comparable metrics.

At 5.3x trailing earnings, RNR trades at a 34% valuation discount to AXS's 8.0x P/E. On an enterprise value basis, RNR's 3.4x EV/EBITDA is more attractive than AXS's 6.2x.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
Market CapShares × price$7.3B$242M$20.0B$13.0B
Enterprise ValueMkt cap + debt − cash$8.0B$212M$21.6B$13.6B
Trailing P/EPrice ÷ TTM EPS8.04x-3.82x-95.37x5.31x
Forward P/EPrice ÷ next-FY EPS est.7.46x582.83x7.66x
PEG RatioP/E ÷ EPS growth rate0.18x
EV / EBITDAEnterprise value multiple6.23x3.38x
Price / SalesMarket cap ÷ Revenue1.12x2.62x6.16x1.02x
Price / BookPrice ÷ Book value/share1.24x1.28x8.24x0.70x
Price / FCFMarket cap ÷ FCF56.10x3.51x
RNR leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

RNR leads this category, winning 5 of 9 comparable metrics.

AXS delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-29 for PRE. PRE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), RNR scores 8/9 vs PRE's 5/9, reflecting strong financial health.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
ROE (TTM)Return on equity+16.9%-28.9%-8.7%+16.6%
ROA (TTM)Return on assets+3.1%-23.7%-3.5%+5.7%
ROICReturn on invested capital+14.8%-20.8%-3.6%+16.0%
ROCEReturn on capital employed+6.0%-21.2%-4.0%+10.7%
Piotroski ScoreFundamental quality 0–95578
Debt / EquityFinancial leverage0.23x0.01x1.05x0.12x
Net DebtTotal debt minus cash$673M-$30M$1.6B$598M
Cash & Equiv.Liquid assets$820M$32M$956M$1.7B
Total DebtShort + long-term debt$1.5B$2M$2.5B$2.3B
Interest CoverageEBIT ÷ Interest expense20.21x-199.93x-5.47x33.28x
RNR leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — AXS and RNR each lead in 2 of 6 comparable metrics.

A $10,000 investment in RNR five years ago would be worth $18,705 today (with dividends reinvested), compared to $1,393 for PRE. Over the past 12 months, PRE leads with a +205.2% total return vs AXS's +1.0%. The 3-year compound annual growth rate (CAGR) favors AXS at 23.9% vs PRE's 7.6% — a key indicator of consistent wealth creation.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
YTD ReturnYear-to-date-4.3%+0.6%+3.1%+10.6%
1-Year ReturnPast 12 months+1.0%+205.2%+96.9%+21.9%
3-Year ReturnCumulative with dividends+90.0%+24.5%+53.0%+45.7%
5-Year ReturnCumulative with dividends+86.4%-86.1%+0.4%+87.1%
10-Year ReturnCumulative with dividends+112.7%-86.1%+1669.1%+176.9%
CAGR (3Y)Annualised 3-year return+23.9%+7.6%+15.2%+13.4%
Evenly matched — AXS and RNR each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EXAS and RNR each lead in 1 of 2 comparable metrics.

RNR is the less volatile stock with a -0.03 beta — it tends to amplify market swings less than PRE's 0.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs PRE's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
Beta (5Y)Sensitivity to S&P 5000.12x0.27x0.12x-0.03x
52-Week HighHighest price in past year$110.34$23.63$104.98$318.20
52-Week LowLowest price in past year$88.07$5.07$38.81$231.17
% of 52W HighCurrent price vs 52-week peak+90.0%+67.2%+99.9%+94.5%
RSI (14)Momentum oscillator 0–10046.837.176.446.9
Avg Volume (50D)Average daily shares traded505K186K4.2M303K
Evenly matched — EXAS and RNR each lead in 1 of 2 comparable metrics.

Analyst Outlook

AXS leads this category, winning 1 of 1 comparable metric.

Analyst consensus: AXS as "Buy", PRE as "Buy", EXAS as "Buy", RNR as "Hold". Consensus price targets imply 126.8% upside for PRE (target: $36) vs -1.6% for EXAS (target: $103). For income investors, AXS offers the higher dividend yield at 1.81% vs RNR's 0.55%.

MetricAXS logoAXSAXIS Capital Hold…PRE logoPREPrenetics Global …EXAS logoEXASExact Sciences Co…RNR logoRNRRenaissanceRe Hol…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$123.88$36.00$103.18$308.33
# AnalystsCovering analysts2914128
Dividend YieldAnnual dividend ÷ price+1.8%+0.6%
Dividend StreakConsecutive years of raises11
Dividend / ShareAnnual DPS$1.80$1.67
Buyback YieldShare repurchases ÷ mkt cap+12.1%0.0%+0.1%+12.3%
AXS leads this category, winning 1 of 1 comparable metric.
Key Takeaway

RNR leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). AXS leads in 1 (Analyst Outlook). 2 tied.

Best OverallRenaissanceRe Holdings Ltd. (RNR)Leads 3 of 6 categories
Loading custom metrics...

AXS vs PRE vs EXAS vs RNR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AXS or PRE or EXAS or RNR a better buy right now?

For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.

7% revenue growth year-over-year, versus 9. 1% for AXIS Capital Holdings Limited (AXS). RenaissanceRe Holdings Ltd. (RNR) offers the better valuation at 5. 3x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate AXIS Capital Holdings Limited (AXS) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AXS or PRE or EXAS or RNR?

On trailing P/E, RenaissanceRe Holdings Ltd.

(RNR) is the cheapest at 5. 3x versus AXIS Capital Holdings Limited at 8. 0x. On forward P/E, AXIS Capital Holdings Limited is actually cheaper at 7. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — AXS or PRE or EXAS or RNR?

Over the past 5 years, RenaissanceRe Holdings Ltd.

(RNR) delivered a total return of +87. 1%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: EXAS returned +1669% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AXS or PRE or EXAS or RNR?

By beta (market sensitivity over 5 years), RenaissanceRe Holdings Ltd.

(RNR) is the lower-risk stock at -0. 03β versus Prenetics Global Limited's 0. 27β — meaning PRE is approximately -941% more volatile than RNR relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — AXS or PRE or EXAS or RNR?

By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.

7% versus 9. 1% for AXIS Capital Holdings Limited (AXS). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -14. 0% for Prenetics Global Limited. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AXS or PRE or EXAS or RNR?

RenaissanceRe Holdings Ltd.

(RNR) is the more profitable company, earning 21. 0% net margin versus -63. 1% for Prenetics Global Limited — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNR leads at 31. 5% versus -40. 5% for PRE. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AXS or PRE or EXAS or RNR more undervalued right now?

On forward earnings alone, AXIS Capital Holdings Limited (AXS) trades at 7.

5x forward P/E versus 582. 8x for Exact Sciences Corporation — 575. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRE: 126. 8% to $36. 00.

08

Which pays a better dividend — AXS or PRE or EXAS or RNR?

In this comparison, AXS (1.

8% yield), RNR (0. 6% yield) pay a dividend. PRE, EXAS do not pay a meaningful dividend and should not be held primarily for income.

09

Is AXS or PRE or EXAS or RNR better for a retirement portfolio?

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, PRE: -86. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AXS and PRE and EXAS and RNR?

These companies operate in different sectors (AXS (Financial Services) and PRE (Healthcare) and EXAS (Healthcare) and RNR (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AXS is a small-cap deep-value stock; PRE is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; RNR is a mid-cap deep-value stock. AXS, RNR pay a dividend while PRE, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AXS

Income & Dividend Stock

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 9%
Run This Screen
Stocks Like

PRE

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 101%
  • Gross Margin > 28%
Run This Screen
Stocks Like

EXAS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 41%
Run This Screen
Stocks Like

RNR

Quality Mega-Cap Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 16%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AXS and PRE and EXAS and RNR on the metrics below

Revenue Growth>
%
(AXS: 12.0% · PRE: 202.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.